Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.84 |
| ▸ | AURKA | O14965 | 13/20 | 0.84 |
| ▸ | TEK | Q02763 | 13/20 | 0.84 |
| ▸ | MET | P08581 | 12/20 | 0.84 |
| ▸ | LCK | P06239 | 10/20 | 0.84 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.84 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.71 |
| ▸ | LYN | P07948 | 3/20 | 0.62 |
| ▸ | ABL1 | P00519 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | FGR | P09769 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | FLT1 | P17948 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774867 | 0.90 | KDR (0.83) | KDRAURKATEKMETLCK | |
| SCHEMBL2748969 | 0.86 | KDR (0.82) | KDRAURKATEKMETLCK | |
| SCHEMBL2746823 | 0.86 | KDR (0.84) | KDRAURKATEKMETLCK | |
| SCHEMBL4548966 | 0.85 | KDR (1.00) | KDRAURKATEKMETLCK | |
| SCHEMBL2748242 | 0.85 | KDR (0.80) | KDRAURKATEKMETLCK | |
| SCHEMBL2746887 | 0.85 | KDR (1.00) | KDRAURKATEKMETLCK | |
| SCHEMBL5771857 | 0.85 | KDR (0.86) | KDRAURKATEKMETLCK | |
| SCHEMBL2747800 | 0.85 | KDR (1.00) | KDRAURKATEKMETLCK | |
| SCHEMBL5769862 | 0.84 | KDR (0.83) | KDRAURKATEKMETLCK | |
| SCHEMBL2746919 | 0.84 | KDR (1.00) | KDRAURKATEKMETLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660503-A1 | NAPHTHALENE CARBOXAMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005021553-A1 | NAPHTHALENE CARBOXAMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | CCNA1, CCNA2, CCNT1 | KDR 30/4885AURKA 2306/4885TEK 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.